Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
about
Practical combination therapy based on pathophysiology of type 2 diabetesPharmacotherapy considerations in diabetes and obesity: setting patients up for success.Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.
P2860
Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@en
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@nl
type
label
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@en
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@nl
prefLabel
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@en
Effect of pioglitazone versus ...... sk markers in type 2 diabetes.
@nl
P2093
P2860
P1433
P1476
Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes
@en
P2093
Antonio Nicolucci
Edoardo Mannucci
Fabio Pellegrini
Giorgia De Berardis
Licia Totani
Virgilio Evangelista
P2860
P2888
P304
P356
10.1007/S12325-013-0003-X
P407
P577
2013-01-22T00:00:00Z